Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
|Articles|May 2, 2014
- Pharmaceutical Technology-05-02-2014
- Volume 38
- Issue 5
Pharmaceutical Technology, May 2014 Issue (PDF)
Click the title above to open the Pharmaceutical Technology May 2014 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 12 years ago
Extractables and Leachables Testingover 12 years ago
Mass Spectrometer Enhances Performance in Protein Analysisover 12 years ago
Data Integrity in the Analytical Laboratoryover 12 years ago
Q&A with Tony Mitchell, Pharma Tech Industriesover 12 years ago
Linking Drug Shortages and Quality Metricsover 12 years ago
EU Steps Up Inspection Effortsover 12 years ago
Aggregation System Improves Analysis of Sub-Visible Particlesover 12 years ago
Boosting New Antibiotic Drug Development in Europeover 12 years ago
Freeze Drying Protein FormulationsAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement